Trial · NCT02754583
Sanitation, Water, and Instruction in Face-washing for Trachoma I/II
NCT02754583, Phase 3, Completed, University of California, San Francisco
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Sanitation, Water, and Instruction in Face-washing for Trachoma I/II. Trials, record NCT02754583. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02754583
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Sanitation, Water, and Instruction in Face-washing for Trachoma I/II
- NCT number
- NCT02754583
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 47,605 participants, actual
- Lead sponsor
- University of California, San Francisco
- Conditions
- Trachoma
- Interventions
- Water, sanitation, and hygiene (WASH) intervention, Standard of care WASH intervention, Azithromycin, Tetracycline, Control
- First posted
- 2016-04-28
- Last updated
- 2026-06-04
Source ClinicalTrials.gov
Registered outcomes20
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Village-specific ocular chlamydia among 0-5 children over time (first trial: WUHA) | 12, 24, 36, 48, 60, 84, 96 months | Multiple time points will be used in a mixed effects regression model of the village-specific ocular chlamydia prevalences over time in 0-5 year olds as assessed by PCR. |
| Primary | Ocular chlamydia among 8-12 year olds (second trial: TAITU-A) | 24 months | Cluster-specific prevalence of ocular chlamydia among individuals aged 8-12 years, compared between the targeted azithromycin arm and the mass azithromycin arm. |
| Primary | Incident ocular chlamydia in 0-5 year-olds (third trial: TAITU-B) | 24 months | Incidence of new ocular chlamydia infection in 0-5 year-olds, compared between the targeted azithromycin arm and the delayed mass azithromycin arm. |
| Primary | Trial-based cost-effectiveness of intervention (intervention costs per percent of chlamydia reduction) | 24 months for TAITU, 36 months for WUHA | The short term analysis is designed to provide insight into whether each intervention (WASH or targeted antibiotics) is effective for our primary trial outcome of reducing ocular chlamydial infection in children. The time horizon of these analyses will be the duration of each trial. |
| Secondary | Quantitative PCR chlamydia load | 12, 24, 36, 48, 60, 84, 96 months | The analysis is proposed to be identical to that of the ocular chlamydia outcome, except that a village-specific index of chlamydia load at baseline and at follow-up times is used instead of prevalence. The analysis is two-sided at an alpha of 0.05. This is a prespecified secondary analysis and will be reported as such. |
| Secondary | Follicular trachoma scores; age-stratified (0-5, 6-9, 10 and up for WUHA; 0-5, 8-12 for TAITU) | 12, 24, 36, 48, 60, 84, 96 months | Follicular trachoma scores (using the 5 level system) will be modeled longitudinally using linear mixed effects regression. Scores are indexed by participant, grader, visit, and village. Participant and village will be modeled as random effects; grader will be modeled as a fixed effect. We will use an AR(1) correlation structure. |
| Secondary | Inflammatory trachoma scores; age-stratified (0-5, 6-9, 10 and up for WUHA; 0-5, 8-12 for TAITU) | 12, 24, 36, 48, 60, 84, 96 months | Inflammatory trachoma grades will be modeled in the same way as Follicular Trachoma. |
| Secondary | Clinical trachoma improvement as measured in photography | 12, 24, 36, 48, 60, 84, 96 months | We anticipate having the following information available. For each child in the sampling frame, we will have a binary improvement score, based on baseline and follow-up photography. We propose to conduct clustered logistic regression (taking into account the clustered nature of the design) using village assignment as the predictor. We will estimate the log odds of the treatment effect. Significance testing will be conducted at 0.05 based on Monte Carlo permutation testing. |
| Secondary | Chlamydial load, individual level analysis | 12, 24, 36, 48, 60, 84, 96 months | Quantitative PCR results at the individual level will be modeled using standard procedures for semi-continuous variables. |
| Secondary | Ocular chlamydia; age-stratified (6-9, 10 and up for WUHA; 8-12 for TAITU) | 12, 24, 36, 48, 60, 84, 96 months | Longitudinal analysis of ocular chlamydia in the age 6-9 group will be modeled at the village level. A similar analysis will consider the 10 and over segment of the population. |
1 to 10 of 20Source ClinicalTrials.gov
See all 20 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers6
The papers the trial lists on ClinicalTrials.gov.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| U10EY023939 | Sanitation, Water, and Instruction in Face-washing for Trachoma | KEENAN, JEREMY DAVID | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO | NATIONAL EYE INSTITUTE | 2014 to 2018 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02754583
GET https://conductscience.org/api/trials/v1/NCT02754583/registered